T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer

References

• Brown FD, Turley SJ. Fibroblastic reticular cells: organization and regulation of the T lymphocyte life cycle. J Immunol. 2015;194(4):1389–14. doi:10.4049/jimmunol.1402520.
   PubMed Web of Science ®Google Scholar
• Liu T, Han C, Wang S, Fang P, Ma Z, Xu L, Yin R. Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy. J Hematol Oncol. 2019;12(1):86. doi:10.1186/s13045-019-0770-1.
   PubMed Web of Science ®Google Scholar
• Lakins MA, Ghorani E, Munir H, Martins CP, Shields JD. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells. Nat Commun. 2018;9(1):948. doi:10.1038/s41467-018-03347-0.
   PubMed Web of Science ®Google Scholar
• Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, Sirven P, Magagna I, Fuhrmann L, Bernard C, et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell. 2018;33:463–479 e410. doi:10.1016/j.ccell.2018.01.011.
   PubMed Web of Science ®Google Scholar
• Cremasco V, Astarita JL, Grauel AL, Keerthivasan S, MacIsaac K, Woodruff MC, Wu M, Spel L, Santoro S, Amoozgar Z, et al. FAP Delineates Heterogeneous and Functionally Divergent Stromal Cells in Immune-Excluded Breast Tumors. Cancer Immunol Res. 2018;6(12):1472–1485. doi:10.1158/2326-6066.CIR-18-0098.
   PubMed Web of Science ®Google Scholar
• Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science. 2010;330(6005):827–830. doi:10.1126/science.1195300.
   PubMed Web of Science ®Google Scholar
• Phipps RP, Penney DP, Keng P, Quill H, Paxhia A, Derdak S, Felch ME. Characterization of two major populations of lung fibroblasts: distinguishing morphology and discordant display of Thy 1 and class II MHC. Am J Respir Cell Mol Biol. 1989;1(1):65–74. doi:10.1165/ajrcmb/1.1.65.
   PubMed Web of Science ®Google Scholar
• Yu M, Guo G, Huang L, Deng L, Chang C-S, Achyut BR, Canning M, Xu N, Arbab AS, Bollag RJ, et al. CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint. Nat Commun. 2020;11(1):515. doi:10.1038/s41467-019-14060-x.
   PubMed Web of Science ®Google Scholar
• Thommen DS, Schreiner J, Muller P, Herzig P, Roller A, Belousov A, Umana P, Pisa P, Klein C, Bacac M, et al. Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunol Res. 2015;3(12):1344–1355. doi:10.1158/2326-6066.CIR-15-0097.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, Yeong JPS, Nahar R, Zhang T, Kared H, et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557:575–579. doi:10.1038/s41586-018-0130-2.
   PubMed Web of Science ®Google Scholar
• Canale FP, Ramello MC, Nunez N, Araujo Furlan CL, Bossio SN, Gorosito Serran M, Tosello Boari J, Del Castillo A, Ledesma M, Sedlik C, et al. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8 + T Cells. Cancer Res. 2018;78(1):115–128. doi:10.1158/0008-5472.CAN-16-2684.
   PubMed Web of Science ®Google Scholar
• Gupta PK, Godec J, Wolski D, Adland E, Yates K, Pauken KE, Cosgrove C, Ledderose C, Junger WG, Robson SC, et al. CD39 Expression Identifies Terminally Exhausted CD8+ T Cells. PLoS Pathog. 2015;11(10):e1005177. doi:10.1371/journal.ppat.1005177.
   PubMed Web of Science ®Google Scholar
• Ganesan A-P, Clarke J, Wood O, Garrido-Martin EM, Chee SJ, Mellows T, Samaniego-Castruita D, Singh D, Seumois G, Alzetani A, et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol. 2017;18(8):940–950. doi:10.1038/ni.3775.
   PubMed Web of Science ®Google Scholar
• Thelen M, Lechner A, Wennhold K, von Bergwelt-Baildon M, Schlosser HA. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8 + T Cells—Letter. Cancer Res. 2018;78(17):5173–5174. doi:10.1158/0008-5472.CAN-18-0873.
   PubMed Web of Science ®Google Scholar
• van Duijn J, van Elsas M, Benne N, Depuydt M, Wezel A, Smeets H, Bot I, Jiskoot W, Kuiper J, Slutter B. CD39 identifies a microenvironment-specific anti-inflammatory CD8+ T-cell population in atherosclerotic lesions. Atherosclerosis. 2019;285:71–78. doi:10.1016/j.atherosclerosis.2019.04.217.
   PubMed Web of Science ®Google Scholar
• Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de Miranda NF, Goodall CP, Blair TC, Fox BA, McDermott JE, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(1):2724. doi:10.1038/s41467-018-05072-0.
   PubMed Web of Science ®Google Scholar
• Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen J-F, Enjyoji K, Linden J, Oukka M, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257–1265. doi:10.1084/jem.20062512.
   PubMed Web of Science ®Google Scholar
• Raczkowski F, Rissiek A, Ricklefs I, Heiss K, Schumacher V, Wundenberg K, Haag F, Koch-Nolte F, Tolosa E, Mittrucker H-W. CD39 is upregulated during activation of mouse and human T cells and attenuates the immune response to Listeria monocytogenes. PLoS One. 2018;13(5):e0197151. doi:10.1371/journal.pone.0197151.
   PubMed Web of Science ®Google Scholar
• Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018;175(4):998–1013 e1020. doi:10.1016/j.cell.2018.10.038.
   PubMed Web of Science ®Google Scholar
• Parodi A, Battaglia F, Kalli F, Ferrera F, Conteduca G, Tardito S, Stringara S, Ivaldi F, Negrini S, Borgonovo G, et al. CD39 is highly involved in mediating the suppression activity of tumor-infiltrating CD8+ T regulatory lymphocytes. Cancer Immunol Immunother. 2013;62(5):851–862. doi:10.1007/s00262-013-1392-z.
   PubMed Web of Science ®Google Scholar
• Bastid J, Regairaz A, Bonnefoy N, Dejou C, Giustiniani J, Laheurte C, Cochaud S, Laprevotte E, Funck-Brentano E, Hemon P, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res. 2015;3(3):254–265. doi:10.1158/2326-6066.CIR-14-0018.
   PubMed Web of Science ®Google Scholar
• Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14(10):1014–1022. doi:10.1038/ni.2703.
   PubMed Web of Science ®Google Scholar
• Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell’Acqua ML, et al. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110(4):1225–1232. doi:10.1182/blood-2006-12-064527.
   PubMed Web of Science ®Google Scholar
• Gu J, Ni X, Pan X, Lu H, Lu Y, Zhao J, Guo Zheng S, Hippen KL, Wang X, Lu L. Human CD39hi regulatory T cells present stronger stability and function under inflammatory conditions. Cell Mol Immunol. 2017;14(6):521–528. doi:10.1038/cmi.2016.30.
   PubMed Web of Science ®Google Scholar
• Bai A, Moss A, Rothweiler S, Serena Longhi M, Wu Y, Junger WG, Robson SC. NADH oxidase-dependent CD39 expression by CD8+ T cells modulates interferon gamma responses via generation of adenosine. Nat Commun. 2015;6(1):8819. doi:10.1038/ncomms9819.
   PubMed Web of Science ®Google Scholar
• Park Y-J, Ryu H, Choi G, Kim B-S, Hwang ES, Kim HS, Chung Y. IL-27 confers a protumorigenic activity of regulatory T cells via CD39. Proc Natl Acad Sci U S A. 2019;116(8):3106–3111. doi:10.1073/pnas.1810254116.
   PubMed Web of Science ®Google Scholar
• Li J, Wang L, Chen X, Li L, Li Y, Ping Y, Huang L, Yue D, Zhang Z, Wang F, et al. CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-beta-mTOR-HIF-1 signaling in patients with non-small cell lung cancer. Oncoimmunology. 2017;6:e1320011. doi:10.1080/2162402X.2017.1320011.
   PubMed Web of Science ®Google Scholar
• Karakasheva TA, Lin EW, Tang Q, Qiao E, Waldron TJ, Soni M, Klein-Szanto AJ, Sahu V, Basu D, Ohashi S, et al. IL-6 Mediates Cross-Talk between Tumor Cells and Activated Fibroblasts in the Tumor Microenvironment. Cancer Res. 2018;78(17):4957–4970. doi:10.1158/0008-5472.CAN-17-2268.
   PubMed Web of Science ®Google Scholar
• Sun J, Dodd H, Moser EK, Sharma R, Braciale TJ. CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat Immunol. 2011;12(4):327–334. doi:10.1038/ni.1996.
   PubMed Web of Science ®Google Scholar
• Pot C, Jin H, Awasthi A, Liu SM, Lai C-Y, Madan R, Sharpe AH, Karp CL, Miaw S-C, Ho I-C, et al. Cutting edge: IL-27 induces the transcription factor c-Maf, cytokine IL-21, and the costimulatory receptor ICOS that coordinately act together to promote differentiation of IL-10-producing Tr1 cells. J Immunol. 2009;183(2):797–801. doi:10.4049/jimmunol.0901233.
   PubMed Web of Science ®Google Scholar
• DeLong JH, O’Hara Hall A, Rausch M, Moodley D, Perry J, Park J, Phan AT, Beiting DP, Kedl RM, Hill JA, et al. IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors. Immunohorizons. 2019;3(1):13–25. doi:10.4049/immunohorizons.1800083.
   PubMedGoogle Scholar
• Kündig TM, Bachmann MF, DiPaolo C, Simard JJ, Battegay M, Lother H, Gessner A, Kühlcke K, Ohashi PS, Hengartner H, et al. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science. 1995;268(5215):1343–1347. doi:10.1126/science.7761853.
   PubMed Web of Science ®Google Scholar
• Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013;110(50):20212–20217. doi:10.1073/pnas.1320318110.
   PubMed Web of Science ®Google Scholar
• Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean M-C, Validire P, Trautmann A, Mami-Chouaib F, Donnadieu E. Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 2012;122(3):899–910. doi:10.1172/JCI45817.
   PubMed Web of Science ®Google Scholar
• Umetsu DT, Pober JS, Jabara HH, Fiers W, Yunis EJ, Burakoff SJ, Reiss CS, Geha RS. Human dermal fibroblasts present tetanus toxoid antigen to antigen-specific T cell clones. J Clin Invest. 1985;76(1):254–260. doi:10.1172/JCI111955.
   PubMed Web of Science ®Google Scholar
• Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, Teinor JA, Belleau P, Biffi G, Lucito MS, et al. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov. 2019;9(8):1102–1123. doi:10.1158/2159-8290.CD-19-0094.
   PubMed Web of Science ®Google Scholar
• Clarke J, Panwar B, Madrigal A, Singh D, Gujar R, Wood O, Chee SJ, Eschweiler S, King EV, Awad AS, et al. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. J Exp Med. 2019;216(9):2128–2149. doi:10.1084/jem.20190249.
   PubMed Web of Science ®Google Scholar
• Thommen DS, Koelzer VH, Herzig P, Roller A, Trefny M, Dimeloe S, Kiialainen A, Hanhart J, Schill C, Hess C, et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med. 2018;24(7):994–1004. doi:10.1038/s41591-018-0057-z.
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Klampatsa A, Thompson JC, Martinez MC, Hwang W-T, Rao AS, Standalick JE, Kim S, Cantu E, Litzky LA, et al. Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non–Small Cell Lung Cancer. Cancer Immunol Res. 2019;7(6):896–909. doi:10.1158/2326-6066.CIR-18-0713.
   PubMed Web of Science ®Google Scholar
• Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res. 2014;2:154–166. doi:10.1158/2326-6066.CIR-13-0027.
   PubMed Web of Science ®Google Scholar
• Gorchs L, Hellevik T, Bruun JA, Camilio KA, Al-Saad S, Stuge TB, Martinez-Zubiaurre I. Cancer-associated fibroblasts from lung tumors maintain their immunosuppressive abilities after high-dose irradiation. Front Oncol. 2015;5:87. doi:10.3389/fonc.2015.00087.
   PubMed Web of Science ®Google Scholar
• Nazareth MR, Broderick L, Simpson-Abelson MR, Kelleher RJ Jr., Yokota SJ, Bankert RB. Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells. J Immunol. 2007;178(9):5552–5562. doi:10.4049/jimmunol.178.9.5552.
   PubMed Web of Science ®Google Scholar
• Barnas JL, Simpson-Abelson MR, Brooks SP, Kelleher RJ Jr., Bankert RB. Reciprocal functional modulation of the activation of T lymphocytes and fibroblasts derived from human solid tumors. J Immunol. 2010;185(5):2681–2692. doi:10.4049/jimmunol.1000896.
   PubMed Web of Science ®Google Scholar
• Gorchs L, Fernandez Moro C, Bankhead P, Kern KP, Sadeak I, Meng Q, Rangelova E, Kaipe H. Human Pancreatic Carcinoma-Associated Fibroblasts Promote Expression of Co-inhibitory Markers on CD4+ and CD8+ T-Cells. Front Immunol. 2019;10:847. doi:10.3389/fimmu.2019.00847.
   PubMed Web of Science ®Google Scholar
• Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med. 2010;207(10):2187–2194. doi:10.1084/jem.20100643.
   PubMed Web of Science ®Google Scholar
• Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I. Dual Faces of IFNγ in Cancer Progression: a Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. Clin Cancer Res. 2016;22(10):2329–2334. doi:10.1158/1078-0432.CCR-16-0224.
   PubMed Web of Science ®Google Scholar
• Horton BL, Williams JB, Cabanov A, Spranger S, Gajewski TF. Intratumoral CD8 + T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. Cancer Immunol Res. 2018;6(1):14–24. doi:10.1158/2326-6066.CIR-17-0249.
   PubMed Web of Science ®Google Scholar
• AH D, CF N, DJ S. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of Activating Cytokines and Evidence for Independent Production the Journal of Immunology. 1988;141:2407–2412.
   Google Scholar
• Sanceau J, Wijdenes J, Revel M, Wietzerbin J:IL-6. and IL-6 receptor modulation by IFN-gamma and tumor necrosis factor-alpha in human monocytic cell line (THP-1). Priming Effect of IFN-gamma J Immunol. 1991;147:2630–2637.
   PubMed Web of Science ®Google Scholar
• Ohmori Y, Schreiber RD, Hamilton TA. Synergy between Interferon-γ and Tumor Necrosis Factor-α in Transcriptional Activation Is Mediated by Cooperation between Signal Transducer and Activator of Transcription 1 and Nuclear Factor κB. J Biol Chem. 1997;272(23):14899–14907. doi:10.1074/jbc.272.23.14899.
   PubMed Web of Science ®Google Scholar
• Pechhold K, Patterson NB, Craighead N, Lee KP, June CH, Harlan DM. Inflammatory cytokines IFN-gamma plus TNF-alpha induce regulated expression of CD80 (B7-1) but not CD86 (B7-2) on murine fibroblasts. J Immunol. 2015;5:4921–4929.
   Google Scholar
• Ju X, Zhang H, Zhou Z, Wang Q. Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy. Am J Cancer Res. 2020;10:1–11.
   PubMed Web of Science ®Google Scholar
• Yoshida H, Hunter CA. The immunobiology of interleukin-27. Annu Rev Immunol. 2015;33(1):417–443. doi:10.1146/annurev-immunol-032414-112134.
   PubMed Web of Science ®Google Scholar
• Yoshimoto T, Morishima N, Mizoguchi I, Shimizu M, Nagai H, Oniki S, Oka M, Nishigori C, Mizuguchi J. Antiproliferative activity of IL-27 on melanoma. J Immunol. 2008;180(10):6527–6535. doi:10.4049/jimmunol.180.10.6527.
   PubMed Web of Science ®Google Scholar
• Cocco C, Giuliani N, Di Carlo E, Ognio E, Storti P, Abeltino M, Sorrentino C, Ponzoni M, Ribatti D, Airoldi I. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res. 2010;16(16):4188–4197. doi:10.1158/1078-0432.CCR-10-0173.
   PubMed Web of Science ®Google Scholar
• Morishima N, Owaki T, Asakawa M, Kamiya S, Mizuguchi J, Yoshimoto T. Augmentation of Effector CD8+ T Cell Generation with Enhanced Granzyme B Expression by IL-27. J Immunol. 2005;175(3):1686–1693. doi:10.4049/jimmunol.175.3.1686.
   PubMed Web of Science ®Google Scholar
• Schneider R, Yaneva T, Beauseigle D, El-Khoury L, Arbour N. IL-27 increases the proliferation and effector functions of human naïve CD8+ T lymphocytes and promotes their development into Tc1 cells. Eur J Immunol. 2011;41(1):47–59. doi:10.1002/eji.201040804.
   PubMed Web of Science ®Google Scholar
• Salcedo R, Stauffer JK, Lincoln E, Back TC, Hixon JA, Hahn C, Shafer-Weaver K, Malyguine A, Kastelein R, Wigginton JM. IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: role for CD8+ T Cells. J Immunol. 2004;173(12):7170–7182. doi:10.4049/jimmunol.173.12.7170.
   PubMed Web of Science ®Google Scholar
• Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, Kuchroo VK, Oukka M, Weiner HL. A dominant function for interleukin 27 in generating interleukin 10–producing anti-inflammatory T cells. Nat Immunol. 2007;8(12):1380–1389. doi:10.1038/ni1541.
   PubMed Web of Science ®Google Scholar
• Hirahara K, Ghoreschi K, Yang X-P, Takahashi H, Laurence A, Vahedi G, Sciume G, Hall AO, Dupont CD, Francisco LM, et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity. 2012;36(6):1017–1030. doi:10.1016/j.immuni.2012.03.024.
   PubMed Web of Science ®Google Scholar
• Zhu C, Sakuishi K, Xiao S, Sun Z, Zaghouani S, Gu G, Wang C, Tan DJ, Wu C, Rangachari M, et al. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction. Nat Commun. 2015;6(1):6072. doi:10.1038/ncomms7072.
   PubMed Web of Science ®Google Scholar
• Huang Z, Zak J, Pratumchai I, Shaabani N, Vartabedian VF, Nguyen N, Wu T, Xiao C, Teijaro JR. IL-27 promotes the expansion of self-renewing CD8+ T cells in persistent viral infection. J Exp Med. 2019;216(8):1791–1808. doi:10.1084/jem.20190173.
   PubMed Web of Science ®Google Scholar
• Dong S, Zhang X, He Y, Xu F, Li D, Xu W, Wang H, Yin Y, Cao J. Synergy of IL-27 and TNF-α in Regulating CXCL10 Expression in Lung Fibroblasts. Am J Respir Cell Mol Biol. 2013;48(4):518–530. doi:10.1165/rcmb.2012-0340OC.
   PubMed Web of Science ®Google Scholar
• Wong CK, Chen DP, Tam LS, Li EK, Yin YB, Lam CW. Effects of inflammatory cytokine IL-27 on the activation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Res Ther. 2010;12(4):R129. doi:10.1186/ar3067.
   PubMed Web of Science ®Google Scholar
• Patel MV, Shen Z, Rossoll RM, Wira CR. IL-27 Expression and Responsiveness in Human Uterine Epithelial Cells and Fibroblasts In Vitro and the Role of Estradiol. J Interferon Cytokine Res. 2018;38(3):101–110. doi:10.1089/jir.2017.0038.
   PubMed Web of Science ®Google Scholar
• Cao W, Fang F, Gould T, Li X, Kim C, Gustafson C, Lambert S, Weyand CM, Goronzy JJ. Ecto-NTPDase CD39 is a negative checkpoint that inhibits follicular helper cell generation. J Clin Invest. 2020;130(7):3422–3436. doi:10.1172/JCI132417.
   PubMed Web of Science ®Google Scholar
• Fang F, Yu M, Cavanagh MM, Hutter Saunders J, Qi Q, Ye Z, Le Saux S, Sultan W, Turgano E, Dekker CL, et al. Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals. Cell Rep. 2016;14:1218–1231.
   PubMed Web of Science ®Google Scholar
• Young A, Ngiow SF, Barkauskas DS, Sult E, Hay C, Blake SJ, Huang Q, Liu J, Takeda K, Teng ML, et al. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. Cancer Cell. 2016;30(3):391–403. doi:10.1016/j.ccell.2016.06.025.
   PubMed Web of Science ®Google Scholar
• Hilchey SP, Kobie JJ, Cochran MR, Secor-Socha S, Wang JC, Hyrien O, Burack WR, Mosmann TR, Quataert SA, Bernstein SH. Human Follicular Lymphoma CD39+-Infiltrating T Cells Contribute to Adenosine-Mediated T Cell Hyporesponsiveness. J Immunol. 2009;183(10):6157–6166. doi:10.4049/jimmunol.0900475.
   PubMed Web of Science ®Google Scholar
• Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017;127(3):929–941. doi:10.1172/JCI89455.
   PubMed Web of Science ®Google Scholar
• Mascanfroni ID, Takenaka MC, Yeste A, Patel B, Wu Y, Kenison JE, Siddiqui S, Basso AS, Otterbein LE, Pardoll DM, et al. Metabolic control of type 1 regulatory T cell differentiation by AHR and HIF1-α. Nat Med. 2015;21(6):638–646. doi:10.1038/nm.3868.
   PubMed Web of Science ®Google Scholar